Serum zinc as a factor predicting response to interferon-α2b therapy in children with chronic hepatitis B

Simple item page
dc.contributor.authorÖzbal E.
dc.contributor.authorHelvaci M.
dc.contributor.authorKasirga E.
dc.contributor.authorAkdenizoǧlu F.
dc.contributor.authorKizilgüneşler A.
dc.date.accessioned2024-07-22T08:25:15Z
dc.date.available2024-07-22T08:25:15Z
dc.date.issued2002
dc.description.abstractAlthough it has been unclear why more than 50% of children with chronic hepatitis B virus infection do not respond to interferon therapy, in some instances resistance to interferon probably is caused by an inability to stimulate appropriately cellular immune responses to hepatitis B virus. It is known that immune integrity is tightly linked to zinc status. We examined the relationship between serum zinc levels and response to interferon (INF)-α therapy in children with chronic hepatitis B. Twenty-five children with chronic hepatitis B infection were injected with 5 × 106 units/m2 recombinant IFN-α 2b subcutaneously three times weekly for 9 mo. Children were followed for at least 9 mo after the end of therapy. Sustained response was obtained in eight (32%) patients. Although initial serum zinc and alanine aminotransferase levels were significantly higher; initial hepatitis B Virus (HBV)-DNA values, hepatic activity index, periportal necrosis, and fibrosis scores were significantly lower in sustained responders than in nonresponders. Mean baseline serum zinc, alanine aminotransferase and HBV-DNA values, histologic activity index, periportal necrosis, and fibrosis scores were predictive of response to IFN-α 2b therapy. These findings suggest that serum zinc levels might be used as a factor predicting response to interferon-α 2b therapy, and so may help in identifying those children with a better chance of response.
dc.identifier.DOI-ID10.1385/BTER:90:1-3:31
dc.identifier.issn01634984
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/20345
dc.language.isoEnglish
dc.subjectAdolescent
dc.subjectChild
dc.subjectChild, Preschool
dc.subjectFemale
dc.subjectHepatitis B, Chronic
dc.subjectHumans
dc.subjectInterferon Alfa-2b
dc.subjectLiver Cirrhosis
dc.subjectMale
dc.subjectTime Factors
dc.subjectTreatment Outcome
dc.subjectZinc
dc.subjectDNA viruses
dc.subjectHepatitis B virus
dc.subjectalanine aminotransferase
dc.subjectalpha2b interferon
dc.subjectzinc
dc.subjectadolescent
dc.subjectalanine aminotransferase blood level
dc.subjectantibiotic resistance
dc.subjectarticle
dc.subjectcellular immunity
dc.subjectchild
dc.subjectclinical article
dc.subjectcontrolled study
dc.subjectDNA virus
dc.subjectfemale
dc.subjectfollow up
dc.subjecthepatitis B
dc.subjectHepatitis B virus
dc.subjecthuman
dc.subjecthuman tissue
dc.subjectliver fibrosis
dc.subjectliver function
dc.subjectliver histology
dc.subjectliver necrosis
dc.subjectmale
dc.subjectprediction
dc.subjectscoring system
dc.subjecttreatment outcome
dc.subjectzinc blood level
dc.titleSerum zinc as a factor predicting response to interferon-α2b therapy in children with chronic hepatitis B
dc.typeArticle

Files

Collections

Scopus Koleksiyonu